癌症中pyroptosis的表观遗传调节:分子病原和向策略
Ruo-Nan Zhang1, Zhi-Qian Jing1, Lu Zhang1
1State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Frontier Science Center for Immunology and Metabolism, Wuhan University, China.
Cancer letters
|September 28, 2023
概括
表观遗传学可以调节热亡,这是一种细胞死亡过程,可以将"冷瘤"转化为"热瘤". 向表观遗传调节的火死提供了癌症免疫治疗的有前途的新策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 免疫检查点阻塞疗法已经改变了癌症治疗,但面临着瘤微环境 (TME) 的挑战.
- 在TME中的免疫抑制细胞和分子可以限制免疫检查点抑制剂的疗效.
- 作为一种被编程细胞死亡的灭,可以通过改变TME来增强抗瘤免疫力.
研究的目的:
- 审查癌症中热的机制.
- 总结表观遗传学在调节热的作用.
- 讨论针对表观遗传调节的烧灭症的治疗策略.
主要方法:
- 审查现有的关于热致死,表观遗传学和癌症免疫治疗的文献.
- 对表观遗传机制的分析,包括DNA甲基化,基因素修饰和非编码RNA.
- 讨论针对表观遗传调节的烧灭症的向策略.
主要成果:
- 表观遗传学,包括DNA甲基化,基因组修饰和非编码RNA,显著调节热.
- 热致死的表观遗传调节会影响瘤发生和瘤微环境.
- 向表观遗传调节的热死提供了一个新的治疗途径.
结论:
- 皮रोप托斯的表观遗传调节是癌症发展和治疗反应的关键因素.
- 向表观遗传调节的活灭菌具有显著的潜力,可以提高癌症免疫疗法的疗效.
- 进一步研究表观遗传调节的热症可能会导致先进的癌症治疗策略.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


